Pfizer beat Wall Street estimates for Q1 profit and slightly raised the company’s 2019 earnings forecast as the largest U.S. drugmaker reined in costs and recorded higher Ibrance and Prevnar sales.
Eli Lilly reported lower-than-expected first-quarter 2019 sales for the company’s top-selling diabetes drug Trulicity, due in part to patient affordability programs.
Fresenius Kabi is investing $100 million in expanding the German company’s manufacturing campus in Wilson County, North Carolina, which will add at least 445 new jobs.
The U.S. patent office rejected a filing by Alvogen Pine Brook for a review challenging patents on Celgene’s blockbuster myeloma drug Revlimid.
W2O – an innovative, analytics-driven, digital-first marketing and communications firm – reported a 23 percent increase in revenue to $177 million in 2018 from $144 million in 2017.
Celgene Corporation reported net product sales of nearly $3.81 billion for the second quarter of 2018, a 17 percent increase from the same period in 2017.
This chart shows the 2016 and 2015 revenue and R&D figures for some of the world’s leading biotech and biopharma companies.
Teva Accelerates its Emerging Markets Growth Strategy with the Acquisition of Rimsa, a Leading Independent Pharmaceutical Company in Mexico with a Portfolio of Products and Patents in Latin America
Active Pharmaceutical Ingredients, Active Pharmaceutical Ingredients (APIs), Emerging Markets, Financials, Latin America, M&A, M&A, Mexico, Specialty PharmaStrategic Move Enhances Teva’s Presence in Mexico, the Second Largest Market in Latin America and a Major Emerging Market Brings a Portfolio of Differentiated, Patent-Protected, Fixed-Dose Medicine Combinations, Strong Brand […]
